Sitagliptin

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Lua error in package.lua at line 80: module 'strict' not found.

Sitagliptin
Sitagliptin.svg
Sitagliptin 3D.png
Systematic (IUPAC) name
(R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a606023
Licence data EMA:Link, US FDA:link
Pregnancy
category
  • AU: B3
  • US: B (No risk in non-human studies)
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Routes of
administration		 Oral
Pharmacokinetic data
Bioavailability 87%
Protein binding 38%
Metabolism Hepatic (CYP3A4- and CYP2C8-mediated)
Biological half-life 8 to 14 h[1]
Excretion Renal (80%)[1]
Identifiers
CAS Number 486460-32-6 YesY
ATC code A10BH01 (WHO)
PubChem CID: 4369359
IUPHAR/BPS 6286
DrugBank DB01261 YesY
ChemSpider 3571948 YesY
UNII QFP0P1DV7Z YesY
ChEBI CHEBI:40237 YesY
ChEMBL CHEMBL1422 YesY
Chemical data
Formula C16H15F6N5O
Molecular mass 407.314 g/mol
  • Fc1cc(c(F)cc1F)C[C@@H](N)CC(=O)N3Cc2nnc(n2CC3)C(F)(F)F
  • InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 YesY
  • Key:MFFMDFFZMYYVKS-SECBINFHSA-N YesY
  (verify)

Sitagliptin (INN; Listeni/sɪtəˈɡlɪptɪn/, previously identified as MK-0431 and marketed as the phosphate salt under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed, and is marketed, by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2.[2] The benefit of this medicine is its fewer side effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. While safety is its advantage, efficacy is often challenged as it is often recommended to be combined with other agents such as metformin.

Adverse effects

Side effects are as common with sitagliptin (whether used alone or with metformin or pioglitazone) as they were with placebo, except for rare nausea and common cold-like symptoms, including photosensitivity.[3] There is no significant difference in the occurrence of hypoglycemia between placebo and sitagliptin.[3][4][5] In those taking sulphonylureas there is an increased risk of low blood sugar.[6]

There have been several postmarketing reports of pancreatitis (some fatal) in people treated with sitagliptin and other DPP-4 inhibitors,[7] and the U.S. package insert carries a warning to this effect,[8] although the causal link between sitagliptin and pancreatitis has not yet been fully substantiated.[2] One study with lab rats published 2009 concluded that some possible risks of pancreatitis, or pancreatic cancer from sitagliptin may be reduced when it is used with metformin. However, while DDP-4 inhibitors show an increase in such risk factors, as of 2009, there is no reported increase in pancreatic cancer in individuals taking DDP-4 inhibitors.[9]

They may cause severe joint pain.[10]

The existence of rare case reports of renal failure and hypersensitivity reactions is noted in the United States prescribing information, but a causative role for sitagliptin has not been established.[11]

Mechanism of action

<templatestyles src="Module:Hatnote/styles.css"></templatestyles>

See also: Dipeptidyl peptidase-4 inhibitors

Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones released in response to a meal.[12] By preventing GLP-1 and GIP inactivation, they are able to increase the secretion of insulin and suppress the release of glucagon by the alpha cells of the pancreas. This drives blood glucose levels towards normal. As the blood glucose level approaches normal, the amounts of insulin released and glucagon suppressed diminishes, thus tending to prevent an "overshoot" and subsequent low blood sugar (hypoglycemia) which is seen with some other oral hypoglycemic agents.

Sitagliptin has been shown to lower HbA1c level by about 0.7% points versus placebo. It is slightly less effective than metformin when used as a monotherapy. It does not cause weight gain and has less hypoglycemia compared to sulfonylureas. Sitagliptin is recommended as a second line drug (in combination with other drugs) after the combination of diet/exercise and metformin fails.[13]

History

Sitagliptin was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2006,[14] and is marketed in the US as Januvia by Merck & Co. On April 2, 2007, the FDA approved an oral combination of sitagliptin and metformin marketed in the US as Janumet. On October 7, 2011, the FDA approved an oral combination of sitagliptin and simvastatin marketed in the US as Juvisync.[15]


See also

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  1. ↑ 1.0 1.1 Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ 2.0 2.1 Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ 3.0 3.1 Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ http://dermatology.cdlib.org/1802/04_csp/09_11-00188/article.html
  5. ↑ http://www.ehealthme.com/ds/januvia/photosensitivity+reaction
  6. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  7. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  8. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  9. ↑ Aleksey V. Matveyenko, Sarah Dry, Heather I. Cox, Artemis Moshtaghian1, Tatyana Gurlo, Ryan Galasso, Alexandra E. Butler and Peter C. Butler, Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes - Interactions With Metformin Diabetes July 2009 vol. 58 no. 7 1604-1615
  10. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  11. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  12. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  13. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  14. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  15. ↑ Lua error in package.lua at line 80: module 'strict' not found.
Retrieved from "https://infogalactic.com/w/index.php?title=Sitagliptin&oldid=721631657"